NYSE:GMED - Globus Medical Stock Price, Forecast & News

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Globus Medical Inc (NYSE:GMED) announced its earnings results on Thursday, February, 20th. The medical device company reported $0.49 EPS for the quarter, missing analysts' consensus estimates of $0.52 by $0.03. The medical device company had revenue of $211.67 million for the quarter, compared to the consensus estimate of $211.11 million. Globus Medical had a net margin of 19.76% and a return on equity of 13.01%. Globus Medical's revenue was up 8.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.43 EPS. View Globus Medical's Earnings History.

Globus Medical is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Globus Medical.

Globus Medical issued an update on its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of $1.82 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.88. The company issued revenue guidance of $850 million, compared to the consensus revenue estimate of $852.63 million.

9 Wall Street analysts have issued 12-month price targets for Globus Medical's shares. Their forecasts range from $60.00 to $67.00. On average, they anticipate Globus Medical's share price to reach $64.43 in the next year. This suggests a possible upside of 16.4% from the stock's current price. View Analyst Price Targets for Globus Medical.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Globus Medical.

Headlines about GMED stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Globus Medical earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the medical device company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the near term. View News Stories for Globus Medical.

Globus Medical saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,760,000 shares, an increase of 30.4% from the January 15th total of 1,350,000 shares. Based on an average trading volume of 522,200 shares, the short-interest ratio is currently 3.4 days. Approximately 2.3% of the shares of the stock are sold short. View Globus Medical's Current Options Chain.

Some companies that are related to Globus Medical include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include AbbVie (ABBV), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Alibaba Group (BABA), Intuitive Surgical (ISRG), Novartis (NVS), Bausch Health Companies (BHC), Walt Disney (DIS), Johnson & Johnson (JNJ) and Pfizer (PFE).

Globus Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (6.93%), State Street Corp (2.55%), GW&K Investment Management LLC (1.41%), Standard Life Aberdeen plc (1.31%), AXA (1.23%) and AQR Capital Management LLC (1.21%). Company insiders that own Globus Medical stock include Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz, James R Tobin, Kelly Huller and Steven Payne. View Institutional Ownership Trends for Globus Medical.

GMED stock was sold by a variety of institutional investors in the last quarter, including Nuance Investments LLC, Janus Henderson Group PLC, AQR Capital Management LLC, Renaissance Technologies LLC, Marathon Asset Management LLP, Retirement Systems of Alabama, GW&K Investment Management LLC and Pembroke Management LTD. Company insiders that have sold Globus Medical company stock in the last year include Anthony L Williams, David D Davidar, James R Tobin and Kelly Huller. View Insider Buying and Selling for Globus Medical.

GMED stock was bought by a variety of institutional investors in the last quarter, including AXA, Panagora Asset Management Inc., Goldman Sachs Group Inc., Madison Asset Management LLC, First Trust Advisors LP, Prudential Financial Inc., Point72 Asset Management L.P. and State of Tennessee Treasury Department. View Insider Buying and Selling for Globus Medical.

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GMED stock can currently be purchased for approximately $55.35.

Globus Medical has a market capitalization of $5.50 billion and generates $785.37 million in revenue each year. The medical device company earns $155.21 million in net income (profit) each year or $1.68 on an earnings per share basis. Globus Medical employs 1,800 workers across the globe.View Additional Information About Globus Medical.

The official website for Globus Medical is http://www.globusmedical.com/.

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]